Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Targeting the AXL signaling pathway in ovarian cancer.

Literature DB >> 28401178

Targeting the AXL signaling pathway in ovarian cancer.

Ruby Yun-Ju Huang¹, Jane Antony², Tuan Zea Tan³, David Shao-Peng Tan⁴.

Abstract

In a recent publication in Science Signaling, we showed that a Mes molecular subtype of epithelial ovarian cancer (EOC) harboring epithelial-mesenchymal transition (EMT) features has a unique signaling network downstream of the GAS6/AXL pathway. Our finding leads to a potential strategy for treating the Mes subtype of EOC by targeting AXL.

Entities: Chemical Disease Gene

Keywords: AXL; EMT; epithelial ovarian cancer

Year: 2016 PMID： 28401178 PMCID： PMC5383361 DOI： 10.1080/23723556.2016.1263716

Source DB: PubMed Journal: Mol Cell Oncol ISSN： 2372-3556

10 in total

1. AXL Inhibition Suppresses the DNA Damage Response and Sensitizes Cells to PARP Inhibition in Multiple Cancers.

Authors: Kavitha Balaji; Smruthi Vijayaraghavan; Lauren Averett Byers; Khandan Keyomarsi; Lixia Diao; Pan Tong; Youhong Fan; Jason Pw Carey; Tuyen N Bui; Steve Warner; John V Heymach; Kelly K Hunt; Jing Wang
Journal: Mol Cancer Res Date: 2016-09-26 Impact factor: 5.852

2. The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype-specific therapeutic target for ovarian cancer.

Authors: Jane Antony; Tuan Zea Tan; Zoe Kelly; Jeffrey Low; Mahesh Choolani; Chiara Recchi; Hani Gabra; Jean Paul Thiery; Ruby Yun-Ju Huang
Journal: Sci Signal Date: 2016-10-04 Impact factor: 8.192

3. Resistance to platinum-based chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer.

Authors: Sergio Marchini; Robert Fruscio; Luca Clivio; Luca Beltrame; Luca Porcu; Ilaria Fuso Nerini; Duccio Cavalieri; Giovanna Chiorino; Giorgio Cattoretti; Costantino Mangioni; Rodolfo Milani; Valter Torri; Chiara Romualdi; Alberto Zambelli; Michela Romano; Mauro Signorelli; Silvana di Giandomenico; Maurizio D'Incalci
Journal: Eur J Cancer Date: 2012-08-13 Impact factor: 9.162

4. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance.

Authors: Lauren Averett Byers; Lixia Diao; Jing Wang; Pierre Saintigny; Luc Girard; Michael Peyton; Li Shen; Youhong Fan; Uma Giri; Praveen K Tumula; Monique B Nilsson; Jayanthi Gudikote; Hai Tran; Robert J G Cardnell; David J Bearss; Steven L Warner; Jason M Foulks; Steven B Kanner; Varsha Gandhi; Nancy Krett; Steven T Rosen; Edward S Kim; Roy S Herbst; George R Blumenschein; J Jack Lee; Scott M Lippman; K Kian Ang; Gordon B Mills; Waun K Hong; John N Weinstein; Ignacio I Wistuba; Kevin R Coombes; John D Minna; John V Heymach
Journal: Clin Cancer Res Date: 2012-10-22 Impact factor: 12.531

5. Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival.

Authors: Christine Gjerdrum; Crina Tiron; Torill Høiby; Ingunn Stefansson; Hallvard Haugen; Tone Sandal; Karin Collett; Shan Li; Emmet McCormack; Bjørn Tore Gjertsen; David R Micklem; Lars A Akslen; Carlotta Glackin; James B Lorens
Journal: Proc Natl Acad Sci U S A Date: 2009-12-28 Impact factor: 11.205

6. Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma.

Authors: Wataru Sakai; Elizabeth M Swisher; Céline Jacquemont; Kurapaty Venkatapoorna Chandramohan; Fergus J Couch; Simon P Langdon; Kaitlyn Wurz; Jake Higgins; Emily Villegas; Toshiyasu Taniguchi
Journal: Cancer Res Date: 2009-08-04 Impact factor: 12.701

Review 7. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer.

Authors: David D Bowtell; Steffen Böhm; Ahmed A Ahmed; Paul-Joseph Aspuria; Robert C Bast; Valerie Beral; Jonathan S Berek; Michael J Birrer; Sarah Blagden; Michael A Bookman; James D Brenton; Katherine B Chiappinelli; Filipe Correia Martins; George Coukos; Ronny Drapkin; Richard Edmondson; Christina Fotopoulou; Hani Gabra; Jérôme Galon; Charlie Gourley; Valerie Heong; David G Huntsman; Marcin Iwanicki; Beth Y Karlan; Allyson Kaye; Ernst Lengyel; Douglas A Levine; Karen H Lu; Iain A McNeish; Usha Menon; Steven A Narod; Brad H Nelson; Kenneth P Nephew; Paul Pharoah; Daniel J Powell; Pilar Ramos; Iris L Romero; Clare L Scott; Anil K Sood; Euan A Stronach; Frances R Balkwill
Journal: Nat Rev Cancer Date: 2015-11 Impact factor: 60.716

8. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer.

Authors: Zhenfeng Zhang; Jae Cheol Lee; Luping Lin; Victor Olivas; Valerie Au; Thomas LaFramboise; Mohamed Abdel-Rahman; Xiaoqi Wang; Alan D Levine; Jin Kyung Rho; Yun Jung Choi; Chang-Min Choi; Sang-We Kim; Se Jin Jang; Young Soo Park; Woo Sung Kim; Dae Ho Lee; Jung-Shin Lee; Vincent A Miller; Maria Arcila; Marc Ladanyi; Philicia Moonsamy; Charles Sawyers; Titus J Boggon; Patrick C Ma; Carlota Costa; Miquel Taron; Rafael Rosell; Balazs Halmos; Trever G Bivona
Journal: Nat Genet Date: 2012-07-01 Impact factor: 38.330

9. Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer.

Authors: Tuan Zea Tan; Qing Hao Miow; Ruby Yun-Ju Huang; Meng Kang Wong; Jieru Ye; Jieying Amelia Lau; Meng Chu Wu; Luqman Hakim Bin Abdul Hadi; Richie Soong; Mahesh Choolani; Ben Davidson; Jahn M Nesland; Ling-Zhi Wang; Noriomi Matsumura; Masaki Mandai; Ikuo Konishi; Boon-Cher Goh; Jeffrey T Chang; Jean Paul Thiery; Seiichi Mori
Journal: EMBO Mol Med Date: 2013-05-13 Impact factor: 12.137

10. Epithelial-mesenchymal transition spectrum quantification and its efficacy in deciphering survival and drug responses of cancer patients.

Authors: Tuan Zea Tan; Qing Hao Miow; Yoshio Miki; Tetsuo Noda; Seiichi Mori; Ruby Yun-Ju Huang; Jean Paul Thiery
Journal: EMBO Mol Med Date: 2014-10 Impact factor: 12.137

10 in total

6 in total

1. Synergistic inactivation of AXL: a (cross)road to cure ovarian cancer?

Authors: Chiara Zurzolo
Journal: EMBO Rep Date: 2018-07-02 Impact factor: 8.807

Review 2. Applications of the Chick Chorioallantoic Membrane as an Alternative Model for Cancer Studies.

Authors: Pei-Yu Chu; Angele Pei-Fern Koh; Jane Antony; Ruby Yun-Ju Huang
Journal: Cells Tissues Organs Date: 2021-03-29 Impact factor: 2.208

3. The tumour suppressor OPCML promotes AXL inactivation by the phosphatase PTPRG in ovarian cancer.

Authors: Jane Antony; Elisa Zanini; Zoe Kelly; Tuan Zea Tan; Evdoxia Karali; Mohammad Alomary; Youngrock Jung; Katherine Nixon; Paula Cunnea; Christina Fotopoulou; Andrew Paterson; Sushmita Roy-Nawathe; Gordon B Mills; Ruby Yun-Ju Huang; Jean Paul Thiery; Hani Gabra; Chiara Recchi
Journal: EMBO Rep Date: 2018-06-15 Impact factor: 8.807